Escalier Biosciences develops novel small‑molecule therapeutics targeting the nuclear hormone receptor RORγt to reduce IL‑17 production implicated in psoriasis and other autoimmune disorders. Its lead oral and topical drug candidates are in late‑stage preclinical studies. The company plans to advance its topical compound into the clinic in mid‑2018. Escalier is pursuing both topical and systemic RORγt inhibitors to address unmet needs in efficacy and safety compared with existing topical and oral drugs. Management highlights include CEO Raju Mohan. The company is registered in The Netherlands and maintains an office in Encinitas, California.

Total raised

$19M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2018